These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17971802)

  • 1. What effect does androgen suppression therapy have on frequency and timing of fatal myocardial infarctions?
    Holzbeierlein JM
    Nat Clin Pract Oncol; 2008 Feb; 5(2):74-5. PubMed ID: 17971802
    [No Abstract]   [Full Text] [Related]  

  • 2. Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk?
    Roach M
    J Clin Oncol; 2007 Nov; 25(33):5325-6; author reply 5326. PubMed ID: 18024880
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.
    D'Amico AV; Denham JW; Crook J; Chen MH; Goldhaber SZ; Lamb DS; Joseph D; Tai KH; Malone S; Ludgate C; Steigler A; Kantoff PW
    J Clin Oncol; 2007 Jun; 25(17):2420-5. PubMed ID: 17557956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation.
    Nguyen PL; Chen MH; Goldhaber SZ; Martin NE; Beard CJ; Dosoretz DE; Katin MJ; Ross R; Salenius SA; D'Amico AV
    Cancer; 2011 Jan; 117(2):406-13. PubMed ID: 21108457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reasons against total androgen suppression.
    Robinson MR
    Prog Clin Biol Res; 1990; 359():117-24; discussion 141-53. PubMed ID: 2284287
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
    Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413.
    Taussky D; Bae K; Bahary JP; Roach M; Lawton CA; Shipley WU; Sandler HM
    Urology; 2008 Nov; 72(5):1125-9. PubMed ID: 18314175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
    Spry NA; Galvão DA; Davies R; La Bianca S; Joseph D; Davidson A; Prince R
    BJU Int; 2009 Sep; 104(6):806-12. PubMed ID: 19281463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Watchful waiting beats androgen deprivation therapy in early prostate cancer.
    Brower V
    J Natl Cancer Inst; 2008 Nov; 100(21):1494-6. PubMed ID: 18957680
    [No Abstract]   [Full Text] [Related]  

  • 10. Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade.
    Tanvetyanon T; Choudhury AM
    J Urol; 2004 Apr; 171(4):1627. PubMed ID: 15017238
    [No Abstract]   [Full Text] [Related]  

  • 11. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
    Takeshita H; Kawakami S; Fukui I
    Int J Urol; 2009 Mar; 16(3):337-8. PubMed ID: 19298352
    [No Abstract]   [Full Text] [Related]  

  • 12. The benefits of early androgen blockade.
    Maroni PD; Crawford ED
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the use of histrelin acetate in the treatment of prostate cancer.
    Crawford ED
    BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148
    [No Abstract]   [Full Text] [Related]  

  • 14. [Is a consequential treatment of prostatic carcinoma with antiandrogenic hormones justified?].
    Leisering W
    Z Arztl Fortbild (Jena); 1977 Jul; 71(13):627-9. PubMed ID: 930137
    [No Abstract]   [Full Text] [Related]  

  • 15. Adverse effects of androgen deprivation therapy on persistent genitourinary complications after carbon ion radiotherapy for prostate cancer.
    Ishikawa H; Tsuji H; Kamada T; Hirasawa N; Yanagi T; Mizoe JE; Akakura K; Suzuki H; Shimazaki J; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):78-84. PubMed ID: 18456419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy.
    Palma D; Pickles T
    Cancer; 2008 May; 112(10):2322-3; author reply 2323. PubMed ID: 18327816
    [No Abstract]   [Full Text] [Related]  

  • 17. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing the side effects of androgen-deprivation therapy.
    J Support Oncol; 2007 Feb; 5(2):87-8. PubMed ID: 17348368
    [No Abstract]   [Full Text] [Related]  

  • 19. Metformin for the prevention of androgen deprivation induced metabolic syndrome, obesity and type 2 diabetes.
    Cohen P
    Med Hypotheses; 2009 Feb; 72(2):227-8. PubMed ID: 19038502
    [No Abstract]   [Full Text] [Related]  

  • 20. Is NNT AOK?
    Lee WR
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):640-1. PubMed ID: 15708240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.